In patients with type 2 diabetes and peripheral artery disease who undergo revascularization, cardiovascular and renal benefits of the agents were confirmed without increased risk of limb amputation.
The US-funded GRADE trial shows liraglutide performed best overall when added to metformin, followed by insulin glargine, with sitagliptin and glimepiride trailing. But SGLT2 inhibitors were not included in study.
The Food and Drug Administration said on Tuesday certain samples of sitagliptin, a compound in Merck s diabetes drug Januvia, were contaminated with a possible carcinogen.
Study of 1863 Chinese patients with type 2 diabetes on insulin showed 48% developed clinically meaningful antibodies to insulin. Antibody levels were linked with the type of insulin and oral agents used.